Johnny Hu is a Principal at Menlo Ventures, where he backs early-stage biotech and life science startups developing novel therapeutics and platform technologies. While completing his Ph.D. at Harvard, he helped engineer gene editing tools later licensed by Editas Medicine and Beam Therapeutics.
Before Menlo, he was a Vice President at Longitude Capital and an associate at Omega Funds, with investments including Lexeo, Endeavor, Opna IO, Amunix, and Nuvation Bio. He holds a Ph.D. from Harvard as an NSF Fellow, an M.Phil. from Cambridge as a Gates Scholar, and an A.B. in Chemical and Physical Biology from Harvard.
